Gilenya (fingolimod): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Gilenya 0.5mg hard capsules

Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient groups:

- Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).

or

- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.


Route of administration: Oral
Molecule: fingolimod

Patients' opinions on Gilenya

In brief

General satisfaction level: 10.00/10 Learn more

Treatment's effectiveness: 9.17/10 Learn more

Ease of use: 10.00/10 Learn more

Adherence to prescription: 9.67/10 Learn more

Detected side effects: 4.60/10 Learn more

Improvement in the quality of life: 8.50/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
ellesse
on 02/01/2024

🤗

Your message


avatar
ellesse
on 06/10/2023

😊

Your message

Conditions related to this medication

Fact sheet

Multiple sclerosis

See the fact sheet